Coronary heart disease secondary prevention: Difference between revisions
Esther Lee (talk | contribs) |
Esther Lee (talk | contribs) |
||
Line 23: | Line 23: | ||
==[[Coronary heart disease secondary prevention renin-angiotensin-aldosterone system blockers |Renin-angiotensin-aldosterone system blockers]]== | ==[[Coronary heart disease secondary prevention renin-angiotensin-aldosterone system blockers |Renin-angiotensin-aldosterone system blockers]]== | ||
==[[Coronary heart disease secondary prevention cardiac rehabilitation | Cardiac Rehabilitation]]== | ==[[Coronary heart disease secondary prevention cardiac rehabilitation | Cardiac Rehabilitation]]== | ||
== References == | == References == | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 17:17, 14 November 2012
Coronary heart disease Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Coronary heart disease secondary prevention On the Web |
American Roentgen Ray Society Images of Coronary heart disease secondary prevention |
Risk calculators and risk factors for Coronary heart disease secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Patients who should be treated with secondary prevention are those with established atherosclerosis including peripheral artery disease; carotid artery disease; atherosclerotic aortic disease; diabetes and those with a Framingham Risk Score of > 20%. There are 12 aspects of secondary prevention: Smoking cessation; blood pressure control; lipid-lowering; increasing physical activity; weight loss; diabetes control; antiplatelet agents/anticoagulants; RAS blockers; beta-blockers; depression management; cardiac rehabilitation and influenza vaccine. Please note that secondary prevention guidelines, especially, those involving medication, may differ between UA/NSTEMI; STEMI; and Chronic Stable Angina. Please refer to appropriate page for more specific guidelines.